Aims Triazolam, a triazolobenzodiazepine hypnotic agent, is metabolized by CYP3A4. Diltiazem is an inhibitor of this isozyme. The aim of this study was to determine if diltiazem affects plasma concentrations of triazolam in humans. Methods We investigated the interaction between triazolam and diltiazem in a randomized, three-phase crossover study. Seven healthy male volunteers received orally either a single 0.25 mg dose of triazolam, a 0.25 mg dose of triazolam after a 3-day treatment of diltiazem (180 mg and the elimination half-life prolonged (4.1±2.1 to 7.6±1.9 h; P<0.01). The PSV, EEG, and VAS of the triazolam plus diltiazem group revealed significant differences from the triazolam alone group or the control placebo group. Conclusions Diltiazem markedly affects the pharmacokinetics of triazolam and increases the intensity of its sedative effects. Inhibition of CYP3A isozyme by diltiazem may explain the observed pharmacokinetic interaction. Therefore, triazolam should be avoided when patients are using diltiazem.
Introduction have involved this drug interaction. Therefore, we intended to investigate the interaction between triazolam and diltiazem The calcium channel blocker diltiazem is widely used for treatment of hypertension, angina pectoris, arrhythmias, and in terms of the pharmacokinetics and pharmacodynamics of triazolam. other cardiovascular diseases. Diltiazem has been reported to inhibit hepatic enzyme metabolism in combination with many therapeutic agents that are metabolized by the CYP3A Methods isozyme, for example, nifedipine, carbamazepine, propranolol and cyclosporine [1] . Ohashi et al. [2, 3] showed that the Study design metabolism of nifedipine, a substrate for CYP3A4, was affected by the concomitant use of diltiazem, revealing that Seven healthy male volunteers participated in a randomized, double-blind, three-phase crossover study at intervals of at the effect was dose-dependent and was maintained on a plateau during repeated administration. least 1 week. The subjects, having given written informed consent, ranged in age from 20 to 22 years and weighed Triazolam is a short-acting hypnotic, widely used for treatment of insomnia. Triazolam is metabolised during its 71.1±13.2 (mean±s.d.) kg. This study was approved by the Institutional Review Board of Hamamatsu University absorption and elimination phases by CYP3A4 isozyme [4] . A recent study [5] has reported that metabolism of triazolam School of Medicine. No subject was taking any medication. The subjects received two different pretreatments: 60 mg was inhibited potently by ketoconazole and itraconazole. Midazolam, which resembles triazolam in its chemical diltiazem (two 30 mg tablets, Tanabe Pharmaceutical Company, Ltd) or a matched placebo three times daily for structure, is metabolized via hydroxylation by CYP3A4. In other reports, the metabolism of midazolam was inhibited 3 days and 1 h before triazolam administration (in a total of ten doses). Subjects were unaware of declining blood by ketoconazole, itraconazole [6] , diltiazem and verapamil [7] . However, there have been only limited reports on the pressure, pulse rate, and other physiological responses during the administration of diltiazem. The subjects took the three interaction between triazolam and diltiazem [8] . Some treatments in a randomized a cross-over manner: (1) placebo with diltiazem pretreatment (diltiazem+triazolam). The Recordings were made before and at 0.5, 1, 2, 3, 4, 5, 6 and 8 h after taking the dose. subjects took each dose of 0.25 mg triazolam (0.25 mg tablet, Upjohn, Ltd) or placebo with 150 ml of tap water and remained fasting for 3 h after dosing. −1 h; P<0.001) and the mean C max by After oral administration of triazolam, peak concentrations (C max ) and time to reach the C max (t max ) were read from about 1.7-times (from 2.1±0.7 to 3.6±1.0 ng ml −1 ;
P<0.05).
In addition, the pretreatment prolonged the mean the actual observed data. Table 1 ). The kinetic parameters ranged interindividually: 1.3 to 3.4 times by the trapezoidal rule.
Pharmacodynamics analysis
Peak saccadic velocity of eye movements (PSV), as described by Van et al. [10] was measured before and at 0.5, 1, 2, 3, 4, 5, 6, and 8 h postdose in each of the three trial phases, and the stimulated horizontal displacement (SLE-5100: Nihon Koden Corporation, Tokyo, Japan) at red lights of 50 (±25) degrees, at random intervals, was recorded. The subjects, as quickly as possible, responded to and followed a signal for 30 s. A NeuroPack 5880 (Nihon Koden Corporation, Tokyo, Japan) with high cut filter at 100 Hz was used for the signal collection and analysis.
Electroencephalogram (EEG) registrations were made using silver-silver chloride electrodes at (PC216: SONY, Tokyo, Japan) with a sampling frequency (6) for AUC (0,8h), 0.8 to 3.8 times for C max , and 1.2 to 3.0 administration and was observed to be more effective with the diltiazem pretreatment compared with the control (i.e., placebo+placebo) or placebo+triazolam trial phase (Figure 2) . A statistically significant difference between the The range of alpha-and beta-wave powers in EEG did not differ significantly among the three treatment conditions subjects pretreated with diltiazem+triazolam and those given the control phase (P<0.01), and between pretreatment in the predose phase ( Table 2 ). The change in the mean percentage of alpha-wave range EEG activity after the of diltiazem+triazolam and placebo+triazolam (P<0.05). The mean PSV as indicative of the triazolam pharmacodynadministration of triazolam differed significantly in all electrode positions (P<0.01) between diltiazem+triazolam amic effects was decreased to 70.6% at 1 h for the subjects with placebo+triazolam and to 52.8% at 2 h for those with and placebo+triazolam (Figures 4 and 5) . In contrast, betawave power was increased in Fp 1 and Fp 2 (P<0.05; diltiazem+triazolam. The effect of triazolam on PSV was significantly increased with the diltiazem pretreatment between control and diltiazem+triazolam). After administration of triazolam, these significant changes of alpha-and compared with the placebo pretreatment ( P<0.05). The decreased PSV with the diltiazem pretreatment returned to beta-wave powers in subjects with diltiazem+triazolam were seen for 8 h after the administration of triazolam. the basal levels with time, but without a complete restoration at 8 h after the administration of triazolam.
Using VAS scores, two-way ANOVA showed a statistically Discussion significant difference between the diltiazem+triazolam and placebo+triazolam in the time course (P<0.05). Although
In this study, we assessed the kinetic and dynamic aspects of the interaction between triazolam and diltiazem in young no statistically significant difference was obtained in drowsiness from triazolam between the subjects pretreated with adult volunteers. Pretreatment with diltiazem three times daily for 3 days increased the blood concentration of and without diltiazem (Figure 3) , the mean drowsiness with diltiazem+triazolam tended to increase as compared with triazolam in the study subjects. The difference in mean plasma concentrations of triazolam with and without placebo+triazolam. diltiazem pretreatment was about two-fold. Therefore, we metabolism of triazolam. If diltiazem inhibits the CYP3A isozyme both in the liver and in the wall of the small assume that the resulting increase in the mean pharmacokinetic parameters such as AUC(0,8h), C max , and t 1/2 of intestine, it should be associated with a decrease in the firstpass effect thereby increasing the C max and AUC. Because triazolam led to the significantly increased effects of hypnotic action we measured in the study. A previous study with we observed a prolonged half-life of triazolam, the hepatic metabolism of triazolam appears to be impaired by diltiazem. midazolam, which is extensively metabolized in the liver by CYP3A4, has shown that its pharmacokinetic parameters However, whether either of CYP3A existing in the gut wall or in the liver would be involved preferentially in the were affected by diltiazem and verapamil, and that the AUC for the subjects pretreated with these Ca-antagonizing drugs metabolism of triazolam remains unclear. Diltiazem has been reported to affect the pharmacokinetics was increased by about 4 and 3 times, respectively, in comparison with the placebo pretreatment. In our study, of nifedipine depending on the dosage [2] , and the period of pretreatment [3] . There was no difference reported the AUC of triazolam was increased by about 2.3 times, and the t 1/2 was prolonged by 1.8 times with diltiazem between 3 days and 6 days of treatment. We therefore decided to make the period of pretreatment with diltiazem pretreatment. Thus, our results resembled these reported by Backman et al. [7] and Varhe et al. [8] . Furthermore, previous 3 days. The previous study showed that the AUC of nifedipine was altered (increased 2.4 times) and t 1/2 studies [4, 11] have suggested that diltiazem increased the bioavailability of midazolam, and decreased the clearance (prolonged 1.3 times) with diltiazem [13] . Since the inhibiting effects of diltiazem in that study were the same caused by inhibiting the hepatic CYP3A isozymes. A recent report [12] has indicated that CYP3A4 in the wall of the or weaker than those seen in our study, we presume that both nifedipine and triazolam are metabolized by the same small intestine plays an important role in the first-pass 
